NervGen Pharma Corp. NGEN.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.15M | 7.59M | 7.66M | 7.23M | 8.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.13M | 18.85M | 17.56M | 17.83M | 18.65M |
| Operating Income | -23.13M | -18.85M | -17.56M | -17.83M | -18.65M |
| Income Before Tax | -15.74M | -30.04M | -31.57M | -18.42M | -19.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.74 | -30.04 | -31.57 | -18.42 | -19.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.74M | -30.04M | -31.57M | -18.42M | -19.29M |
| EBIT | -23.13M | -18.85M | -17.56M | -17.83M | -18.65M |
| EBITDA | -23.09M | -18.80M | -17.52M | -17.79M | -18.60M |
| EPS Basic | -0.23 | -0.41 | -0.43 | -0.26 | -0.27 |
| Normalized Basic EPS | -0.15 | -0.26 | -0.27 | -0.16 | -0.17 |
| EPS Diluted | -0.46 | -0.46 | -0.44 | -0.26 | -0.28 |
| Normalized Diluted EPS | -0.15 | -0.26 | -0.27 | -0.16 | -0.17 |
| Average Basic Shares Outstanding | 319.02M | 298.53M | 289.30M | 285.78M | 282.68M |
| Average Diluted Shares Outstanding | 332.64M | 299.49M | 289.30M | 285.78M | 282.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |